DYNC1I2 (Dynein Cytoplasmic 1 Intermediate Chain 2) encodes the intermediate chain 2 (IC2) subunit of the cytoplasmic dynein 1 complex, the primary minus-end-directed microtubule motor in all eukaryotes. Cytoplasmic dynein drives retrograde axonal transport — the movement of organelles, vesicles, proteins, and signaling complexes from the distal axon back toward the cell body. In neurons, this process is essential for synaptic function, organelle homeostasis, protein turnover, and survival signaling. DYNC1I2 is particularly important in the nervous system, and mutations in this gene cause cortical malformations and axonal transport disorders including hereditary spastic paraplegia.
The dynein complex is a massive (~1.5 MDa) ring-shaped AAA+ ATPase machine. The intermediate chains form part of the base of the complex, anchoring the complex to cargo via interactions with adaptor proteins and directly binding microtubules. DYNC1I2 is one of two highly similar intermediate chain genes (DYNC1I1 and DYNC1I2) in vertebrates.
| Attribute |
Value |
| Protein Name |
Cytoplasmic Dynein 1 Intermediate Chain 2 (DIC2) |
| Gene Symbol |
DYNC1I2 |
| UniProt ID |
Q86X29 |
| Alternative Names |
Dynein intermediate chain 2, DIC2, IC2 |
| Molecular Weight |
~71 kDa |
| Protein Length |
~650 amino acids |
| Chromosomal Location |
2q21.3 |
| Subcellular Location |
Cytoplasm, microtubules, axon (retrograde transport) |
| Protein Family |
Dynein intermediate chain family |
¶ Domain Architecture
The DYNC1I2 protein contains multiple functional domains:
N-terminal Cargo-Binding Domain (~350 residues):
- Contains multiple protein-protein interaction motifs
- Binds directly to dynactin complex via the DCTN1 (p150-glued) subunit
- Interacts with cargo adaptor proteins (bicyclopen, RhoBTB3, Hook proteins)
- Homodimerization interface (DYNC1I2 forms homodimers within the dynein complex)
Microtubule-Binding Domain (~200 residues, middle region):
- Binds to the microtubule plus-end track
- Multiple microtubule interaction surfaces
- Couples ATP-driven conformational changes to stepping motion
AAA+ Domains (C-terminal region):
- Six AAA+ modules (AAA1-AAA6) drive the mechanical cycle
- AAA1 is the primary ATPase site; AAA2-AAA4 contribute to mechanochemistry
- AAA5 and AAA6 have regulatory roles
- The ring structure undergoes coordinated ATP hydrolysis cycles to generate force
DYNC1I2 is one of two intermediate chain paralogs that form part of the dynein holoenzyme:
- Dynein homodimer: Two heavy chains (DYNC1H1), each with associated intermediate chains, light intermediate chains, and light chains
- 4 intermediate chains per dynein: Typically DYNC1I2 homodimers, sometimes mixed with DYNC1I1
- Dynactin complex: A separate ~1 MDa complex that activates dynein and increases processivity; DYNC1I2 directly interacts with the dynactin subunit DCTN1 (p150-glued)
- Cargo adaptors: Numerous adaptors (biccnl,-hook1-3, rab11-FIP3, etc.) connect specific cargo to the dynein-dynactin complex
Cytoplasmic dynein powered by DYNC1I2 is the engine of retrograde axonal transport:
What gets transported:
- Vesicular cargo: Endosomes, signaling endosomes, autophagosomes
- Organelles: Mitochondria (in part), lysosomes, Golgi-derived vesicles
- Protein complexes: Neurotrophin signaling endosomes (NGF, BDNF), transcription factor complexes
- Pathogens: Herpesvirus, adenovirus for intracellular transport
- RNA granules: Some neuronal RNA transport
Key transport features:
- Velocity: ~0.5-2 μm/s (slower than kinesin anterograde transport at ~1-3 μm/s)
- Processivity: ~1-2 μm per run; dynactin greatly increases run length to ~5-10 μm
- Direction: Always minus-end (toward cell body) — microtubules are oriented minus-end toward cell body in axons
- Regulation: Multiple mechanisms including phosphorylation, cargo adapters, and regulatory proteins
The dynein motor uses a unique "walking" mechanism distinct from kinesins:
- Dynein binds microtubule: Microtubule-binding domain interacts with tubulin
- ATP binding to AAA1: Drives a conformational change in the linker domain
- Release from microtubule: The mechanical element detaches
- Power stroke: The linker bends, pulling the stalk toward the ring
- Microtubule rebinding: At a new position ~8 nm toward the minus end
- Hydrolysis and recovery: ATP hydrolysis resets the cycle
This produces ~8 nm steps — the tubulin dimer repeat — with variable stepping behavior.
Retrograde neurotrophin signaling:
- NGF and other neurotrophins are internalized at nerve terminals and transported as signaling endosomes toward the cell body
- DYNC1I2/dynein powers this transport, allowing distal signals to activate nuclear transcription programs
- Critical for neuronal survival and plasticity
Organelle and endosome trafficking:
- Retrograde movement of early and late endosomes
- Sorting of endocytic cargo
- Delivery to the soma for degradation or recycling
Mitophagy in neurons:
- Damaged mitochondria in distal axons are engulfed by autophagosomes
- Autophagosomes are transported retrogradely by dynein for lysosomal fusion in the soma
Cell division:
- Dynein positions the nucleus and centrosome during interphase
- Essential for chromosome alignment and spindle organization during mitosis
Impaired axonal transport is a unifying feature of many neurodegenerative diseases:
Hallmarks of transport dysfunction:
- Organelle accumulation at synapses and distal axons
- Swollen, dystrophic axons
- Protein aggregation (often from impaired turnover)
- Neuroinflammation (from impaired immune signaling)
- Distal axon degeneration ("dying-back" pattern)
DYNC1I2 mutations cause autosomal dominant HSP:
- SPG11: Caused by loss-of-function mutations; characterized by spasticity and thin corpus callosum
- SPG15 (ZFYVE26/SPG15): Affects dynein-dynactin interaction
- DYNC1I2 variants disrupt the dynein-dynactin interaction, impairing cargo attachment and processivity
Missense mutations in DYNC1I2 cause cortical malformations:
- Periventricular heterotopia: Neuronal migration arrest
- Polymicrogyria: Abnormal cortical folding
- Microcephaly: Reduced brain size
- Mechanism: Impaired dynein function disrupts neuronal migration during cortical development
Tau-mediated transport impairment:
- Hyperphosphorylated tau accumulates along microtubules, physically obstructing dynein-mediated transport
- Tau also destabilizes microtubules, reducing the track for transport
- Impaired retrograde transport contributes to synaptic dysfunction and neuronal death
APP and Aβ transport:
- APP is processed in the soma and transported to nerve terminals; dynein may contribute to APP trafficking
- Impaired transport disrupts APP processing compartments, potentially increasing Aβ production
- Alpha-synuclein aggregates can impair axonal transport machinery
- Impaired retrograde transport of signaling endosomes reduces survival signals in dopaminergic neurons
- Mitochondrial quality control (mitophagy) in distal axons requires dynein function
- LRRK2 mutations affect microtubule-based transport; interplay with dynein is under investigation
- Motor neurons have extremely long axons — they are particularly vulnerable to transport defects
- Mutations in DCTN1 (dynactin p150-glued) cause ALS-like phenotypes
- TDP-43 aggregation may impair axonal transport
- SMN deficiency in spinal muscular atrophy directly impacts axonal transport
flowchart TD
A["Cargo<br/>(organelle, vesicle, endosome)"] --> B["Cargo Adaptor Protein<br/>(biccnl, HOOK, etc.)"]
B --> C["Dynactin Complex<br/>(activator, processivity factor)"]
C --> D["Dynein Holoenzyme<br/>(DYNC1I2 + DYNC1H1 + LIC + LC)"]
D -->|"ATP hydrolysis<br/>AAA+ domains"| E["Microtubule<br/>(- end direction)"]
E --> F["Cell body<br/>(nucleus, soma)"]
style A fill:#e1f5fe,stroke:#333
style F fill:#c8e6c9,stroke:#333
style E fill:#fff9c4,stroke:#333
Therapeutic strategies are limited but actively researched:
| Strategy |
Approach |
Status |
Notes |
| Microtubule stabilization |
Epothilone D, BMS-984702 |
Phase 1-2 |
Stabilize microtubules to improve transport |
| Dynein activation |
Small molecule activators |
Preclinical |
Enhance dynein function directly |
| Dynactin enhancement |
Protein-based therapeutics |
Discovery |
Increase dynein processivity |
| Reduce tau pathology |
Anti-tau antibodies, kinase inhibitors |
Various |
Remove transport obstacles |
| Gene therapy |
AAV-mediated expression of transport proteins |
Preclinical |
Deliver functional genes |
- Neuronal polarity: Long axons make systemic delivery of therapeutics to neurons extremely difficult
- BBB: Most large molecules do not cross the blood-brain barrier
- Specificity: Enhancing dynein globally may have off-target effects on cell division
- Dosage: Transport needs vary by cargo and cell type — global enhancement may be problematic